Is C-type natriuretic peptide a maternal marker of foetal growth restriction and hypoxaemia?
Dr Mark Oliver, University of Auckland
Failure of the placenta to supply enough nutrition and oxygen to a baby during pregnancy can lead to foetal growth restriction (FGR) and small size at birth. FGR also decreases a baby’s chances of survival and can have negative consequences for health throughout life.
One in three foetal growth restriction cases are missed
Current methods – ultrasound or simply measuring a pregnant woman’s tummy – can miss at least a third of FGR cases in New Zealand. These missed cases are at increased risk of stillbirth and other serious health complications.
A simple maternal blood test may be possible
FGR is usually accompanied by low oxygen content in the baby’s blood, because the placenta is not working properly. Measuring foetal blood oxygen content in utero is not possible in human babies as a routine screening, but we can measure blood oxygen content in foetal sheep blood.
A hormone called C-type natriuretic peptide (CNP), found in the maternal blood of both humans and sheep, may be a marker of low foetal blood oxygen and FGR. While promising, the data we have is still quite limited.
Dr Oliver is leading initial research in sheep
A team from the universities of Auckland and Otago is conducting research using sheep. The study will thoroughly investigate whether CNP in maternal blood could be a useful test for FGR and low foetal oxygen. This would enable more reliable detection using an inexpensive, non-invasive test that doesn’t require specialist skills.
Cure Kids is backing Dr Oliver’s important research
Funding from Cure Kids is enabling this interesting project, which could lead to research in humans and a simple way to significantly improve the diagnosis of foetal growth restriction.